drugset / Trial / NCT02761070
Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this Phase III study is to evaluate the superiority of dose-dense temozolomide (ddTMZ) followed by bevacizumab at ddTMZ failure for glioblastoma at first recurrence or progression, comparing to bevacizumab alone.
Timeline
- Start
- 2016-07-11
- Primary completion
- 2025-11-10
- Completion
- 2025-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |